Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrow View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2013-08-10

AUTHORS

Judith Neukirchen, Uwe Platzbecker, Katja Sockel, Antonis Tsamaloukas, Rainer Haas, Ulrich Germing

ABSTRACT

Immunosuppressive therapy is a therapeutic option for selected low-risk myelodysplastic syndromes (MDS) patients. Besides standard treatment protocols that include ATG and CSA, the humanized CD52 antibody alemtuzumab has been shown to have efficacy in MDS treatment. We report our experience with alemtuzumab in nine MDS RCMD patients. All patients had a hypocellular bone marrow with a blast count <5 % and were classified as intermediate-1 according to the IPSS. We found a response in five patients (60 %); three patients achieved a complete remission 3 and 6 months after the treatment with alemtuzumab, and two patients showed a haematological improvement. Alemtuzumab was administered in a 10-mg dosage for 10 days. Treatment was well tolerated, and no severe side effects were observed. We could confirm the finding that the alemtuzumab is effective and save selected MDS patients. Due to the promising results, further studies, especially with regard to long-term survival and risk of leucemic progression should be initiated. More... »

PAGES

65-69

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00277-013-1859-1

DOI

http://dx.doi.org/10.1007/s00277-013-1859-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1046839559

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23934199


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Alemtuzumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, CD", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Component Transfusion", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Marrow", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "CD52 Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Count", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "DNA (Cytosine-5-)-Methyltransferases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "DNA Methyltransferase 3A", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Evaluation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycoproteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunosuppressive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Subcutaneous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myelodysplastic Syndromes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Remission Induction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Neukirchen", 
        "givenName": "Judith", 
        "id": "sg:person.0643404664.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643404664.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine 1, University Hospital Carl Gustav Carus, Dresden, Germany", 
          "id": "http://www.grid.ac/institutes/grid.412282.f", 
          "name": [
            "Department of Medicine 1, University Hospital Carl Gustav Carus, Dresden, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Platzbecker", 
        "givenName": "Uwe", 
        "id": "sg:person.0670313557.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670313557.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine 1, University Hospital Carl Gustav Carus, Dresden, Germany", 
          "id": "http://www.grid.ac/institutes/grid.412282.f", 
          "name": [
            "Department of Medicine 1, University Hospital Carl Gustav Carus, Dresden, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sockel", 
        "givenName": "Katja", 
        "id": "sg:person.01040552530.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040552530.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Private Practice, Hilden, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Private Practice, Hilden, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tsamaloukas", 
        "givenName": "Antonis", 
        "id": "sg:person.01002544733.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002544733.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Haas", 
        "givenName": "Rainer", 
        "id": "sg:person.01127414674.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127414674.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Germing", 
        "givenName": "Ulrich", 
        "id": "sg:person.01362464041.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.leu.2404747", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011177675", 
          "https://doi.org/10.1038/sj.leu.2404747"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2011.44", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023546509", 
          "https://doi.org/10.1038/leu.2011.44"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1210380", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035428201", 
          "https://doi.org/10.1038/sj.onc.1210380"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2403239", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015449707", 
          "https://doi.org/10.1038/sj.leu.2403239"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-08-10", 
    "datePublishedReg": "2013-08-10", 
    "description": "Immunosuppressive therapy is a therapeutic option for selected low-risk myelodysplastic syndromes (MDS) patients. Besides standard treatment protocols that include ATG and CSA, the humanized CD52 antibody alemtuzumab has been shown to have efficacy in MDS treatment. We report our experience with alemtuzumab in nine MDS RCMD patients. All patients had a hypocellular bone marrow with a blast count <5\u00a0% and were classified as intermediate-1 according to the IPSS. We found a response in five patients (60\u00a0%); three patients achieved a complete remission 3 and 6\u00a0months after the treatment with alemtuzumab, and two patients showed a haematological improvement. Alemtuzumab was administered in a 10-mg dosage for 10\u00a0days. Treatment was well tolerated, and no severe side effects were observed. We could confirm the finding that the alemtuzumab is effective and save selected MDS patients. Due to the promising results, further studies, especially with regard to long-term survival and risk of leucemic progression should be initiated.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00277-013-1859-1", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1358129", 
        "issn": [
          "0939-5555", 
          "1432-0584"
        ], 
        "name": "Annals of Hematology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "93"
      }
    ], 
    "keywords": [
      "hypocellular bone marrow", 
      "bone marrow", 
      "low-risk myelodysplastic syndrome patients", 
      "CD52 antibody alemtuzumab", 
      "complete remission 3", 
      "myelodysplastic syndrome patients", 
      "standard treatment protocol", 
      "lower-risk MDS", 
      "severe side effects", 
      "long-term survival", 
      "RCMD patients", 
      "remission 3", 
      "alemtuzumab treatment", 
      "immunosuppressive therapy", 
      "blast count", 
      "haematological improvement", 
      "antibody alemtuzumab", 
      "therapeutic options", 
      "MDS patients", 
      "MDS treatment", 
      "syndrome patients", 
      "treatment protocol", 
      "alemtuzumab", 
      "side effects", 
      "patients", 
      "Further studies", 
      "treatment", 
      "marrow", 
      "real-life experience", 
      "IPSS", 
      "therapy", 
      "progression", 
      "months", 
      "efficacy", 
      "CsA", 
      "promising results", 
      "survival", 
      "risk", 
      "count", 
      "dosage", 
      "days", 
      "life experiences", 
      "options", 
      "experience", 
      "findings", 
      "response", 
      "study", 
      "protocol", 
      "MD", 
      "ATG", 
      "effect", 
      "improvement", 
      "regard", 
      "results"
    ], 
    "name": "Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrow", 
    "pagination": "65-69", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1046839559"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00277-013-1859-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23934199"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00277-013-1859-1", 
      "https://app.dimensions.ai/details/publication/pub.1046839559"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:38", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_594.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00277-013-1859-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-013-1859-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-013-1859-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-013-1859-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-013-1859-1'


 

This table displays all metadata directly associated to this object as RDF triples.

276 TRIPLES      21 PREDICATES      109 URIs      97 LITERALS      33 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00277-013-1859-1 schema:about N01a7408ed623432684aaa4215179a059
2 N06ac44cbe6ff45969259578816df882b
3 N1620338cda854240b4d3060555a71015
4 N291abcf7c5b84cd9adee2abed0498e77
5 N2cc3eeb3d260499e8be15145013c297f
6 N5310dec7ffcd469bb2f23b572f01b47a
7 N5d1fe0dd856f4dc0ad4e1d9889e37987
8 N63881eab877c4f0eaa913d11c82416fc
9 N65115bfa67664dba977d1ea1aa7118c7
10 N65d9785dcc794590a88492a8978e6ffe
11 N6e7a9bc6ae234688a2eeeaa847d620ae
12 N88ecc442c18b437f8b723a11361bec07
13 N9148c00a6f234de787bce5ffddc82e23
14 Na9d1b7402fb448aba00cc25935fdaab0
15 Naba98dde6c85498f972c76d15f9cc94b
16 Nb34d5437792f4e8ab945aa7c16aba7c4
17 Nc62620586b4e411684ce5b957b06a896
18 Nccb837044e9f41d1bb9cb5634fcb8fd5
19 Nd30434cb6d014dbb92d76c4484dbeeec
20 Nd4c03dabde1d4d06a26680b4555688bd
21 Nd5bd0293e70b489aba16b001813b552b
22 Ne04522abda8448599801db2860c38c15
23 Ne29bbe2676ba419284a31f2d6d58e5d9
24 Nfc990374b7534adb9c069fa805a90433
25 Nfcff759ad56940f585737271958083b8
26 Nff81882a37a94b0bb871e8fda1bad209
27 anzsrc-for:11
28 anzsrc-for:1103
29 schema:author N2a1c1260a24049dab1145ecf242e21fa
30 schema:citation sg:pub.10.1038/leu.2011.44
31 sg:pub.10.1038/sj.leu.2403239
32 sg:pub.10.1038/sj.leu.2404747
33 sg:pub.10.1038/sj.onc.1210380
34 schema:datePublished 2013-08-10
35 schema:datePublishedReg 2013-08-10
36 schema:description Immunosuppressive therapy is a therapeutic option for selected low-risk myelodysplastic syndromes (MDS) patients. Besides standard treatment protocols that include ATG and CSA, the humanized CD52 antibody alemtuzumab has been shown to have efficacy in MDS treatment. We report our experience with alemtuzumab in nine MDS RCMD patients. All patients had a hypocellular bone marrow with a blast count <5 % and were classified as intermediate-1 according to the IPSS. We found a response in five patients (60 %); three patients achieved a complete remission 3 and 6 months after the treatment with alemtuzumab, and two patients showed a haematological improvement. Alemtuzumab was administered in a 10-mg dosage for 10 days. Treatment was well tolerated, and no severe side effects were observed. We could confirm the finding that the alemtuzumab is effective and save selected MDS patients. Due to the promising results, further studies, especially with regard to long-term survival and risk of leucemic progression should be initiated.
37 schema:genre article
38 schema:isAccessibleForFree false
39 schema:isPartOf N5a9371a5fa844e23b821238704726e48
40 N5bf62395afd24fa8b4f6b043030f5b82
41 sg:journal.1358129
42 schema:keywords ATG
43 CD52 antibody alemtuzumab
44 CsA
45 Further studies
46 IPSS
47 MD
48 MDS patients
49 MDS treatment
50 RCMD patients
51 alemtuzumab
52 alemtuzumab treatment
53 antibody alemtuzumab
54 blast count
55 bone marrow
56 complete remission 3
57 count
58 days
59 dosage
60 effect
61 efficacy
62 experience
63 findings
64 haematological improvement
65 hypocellular bone marrow
66 immunosuppressive therapy
67 improvement
68 life experiences
69 long-term survival
70 low-risk myelodysplastic syndrome patients
71 lower-risk MDS
72 marrow
73 months
74 myelodysplastic syndrome patients
75 options
76 patients
77 progression
78 promising results
79 protocol
80 real-life experience
81 regard
82 remission 3
83 response
84 results
85 risk
86 severe side effects
87 side effects
88 standard treatment protocol
89 study
90 survival
91 syndrome patients
92 therapeutic options
93 therapy
94 treatment
95 treatment protocol
96 schema:name Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrow
97 schema:pagination 65-69
98 schema:productId N9b2140e3df5f41df8877fb9720b00be7
99 Na01c3fe172fd472fb3100c8c3e6e10bd
100 Nb0b96c963c344d86ac52289b3300c6ac
101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046839559
102 https://doi.org/10.1007/s00277-013-1859-1
103 schema:sdDatePublished 2022-10-01T06:38
104 schema:sdLicense https://scigraph.springernature.com/explorer/license/
105 schema:sdPublisher N95f49e9dd46642babbd7a1acf1a0cb72
106 schema:url https://doi.org/10.1007/s00277-013-1859-1
107 sgo:license sg:explorer/license/
108 sgo:sdDataset articles
109 rdf:type schema:ScholarlyArticle
110 N01a7408ed623432684aaa4215179a059 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Middle Aged
112 rdf:type schema:DefinedTerm
113 N038288e21340459096f7fdf06e22caa7 rdf:first sg:person.01127414674.14
114 rdf:rest N3f642a23a8ab4108947125a2c3c8c260
115 N06ac44cbe6ff45969259578816df882b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Cell Count
117 rdf:type schema:DefinedTerm
118 N1620338cda854240b4d3060555a71015 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Bone Marrow
120 rdf:type schema:DefinedTerm
121 N210e99fe0b184d64887506a5a7d4b095 rdf:first sg:person.0670313557.25
122 rdf:rest N469b1b7cdc1943dcb6e70b6f5c7bceaa
123 N291abcf7c5b84cd9adee2abed0498e77 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Immunosuppressive Agents
125 rdf:type schema:DefinedTerm
126 N2a1c1260a24049dab1145ecf242e21fa rdf:first sg:person.0643404664.08
127 rdf:rest N210e99fe0b184d64887506a5a7d4b095
128 N2cc3eeb3d260499e8be15145013c297f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Myelodysplastic Syndromes
130 rdf:type schema:DefinedTerm
131 N3f642a23a8ab4108947125a2c3c8c260 rdf:first sg:person.01362464041.20
132 rdf:rest rdf:nil
133 N469b1b7cdc1943dcb6e70b6f5c7bceaa rdf:first sg:person.01040552530.23
134 rdf:rest N8e36e469f642417ea7812a86c4f1461e
135 N5310dec7ffcd469bb2f23b572f01b47a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Injections, Subcutaneous
137 rdf:type schema:DefinedTerm
138 N5a9371a5fa844e23b821238704726e48 schema:issueNumber 1
139 rdf:type schema:PublicationIssue
140 N5bf62395afd24fa8b4f6b043030f5b82 schema:volumeNumber 93
141 rdf:type schema:PublicationVolume
142 N5d1fe0dd856f4dc0ad4e1d9889e37987 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Retrospective Studies
144 rdf:type schema:DefinedTerm
145 N63881eab877c4f0eaa913d11c82416fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Adult
147 rdf:type schema:DefinedTerm
148 N65115bfa67664dba977d1ea1aa7118c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Combined Modality Therapy
150 rdf:type schema:DefinedTerm
151 N65d9785dcc794590a88492a8978e6ffe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Male
153 rdf:type schema:DefinedTerm
154 N6e7a9bc6ae234688a2eeeaa847d620ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Alemtuzumab
156 rdf:type schema:DefinedTerm
157 N88ecc442c18b437f8b723a11361bec07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Remission Induction
159 rdf:type schema:DefinedTerm
160 N8e36e469f642417ea7812a86c4f1461e rdf:first sg:person.01002544733.03
161 rdf:rest N038288e21340459096f7fdf06e22caa7
162 N9148c00a6f234de787bce5ffddc82e23 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Antigens, CD
164 rdf:type schema:DefinedTerm
165 N95f49e9dd46642babbd7a1acf1a0cb72 schema:name Springer Nature - SN SciGraph project
166 rdf:type schema:Organization
167 N9b2140e3df5f41df8877fb9720b00be7 schema:name doi
168 schema:value 10.1007/s00277-013-1859-1
169 rdf:type schema:PropertyValue
170 Na01c3fe172fd472fb3100c8c3e6e10bd schema:name pubmed_id
171 schema:value 23934199
172 rdf:type schema:PropertyValue
173 Na9d1b7402fb448aba00cc25935fdaab0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Blood Component Transfusion
175 rdf:type schema:DefinedTerm
176 Naba98dde6c85498f972c76d15f9cc94b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name CD52 Antigen
178 rdf:type schema:DefinedTerm
179 Nb0b96c963c344d86ac52289b3300c6ac schema:name dimensions_id
180 schema:value pub.1046839559
181 rdf:type schema:PropertyValue
182 Nb34d5437792f4e8ab945aa7c16aba7c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Aged, 80 and over
184 rdf:type schema:DefinedTerm
185 Nc62620586b4e411684ce5b957b06a896 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Glycoproteins
187 rdf:type schema:DefinedTerm
188 Nccb837044e9f41d1bb9cb5634fcb8fd5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Antibodies, Monoclonal, Humanized
190 rdf:type schema:DefinedTerm
191 Nd30434cb6d014dbb92d76c4484dbeeec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name DNA Methyltransferase 3A
193 rdf:type schema:DefinedTerm
194 Nd4c03dabde1d4d06a26680b4555688bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name DNA (Cytosine-5-)-Methyltransferases
196 rdf:type schema:DefinedTerm
197 Nd5bd0293e70b489aba16b001813b552b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Female
199 rdf:type schema:DefinedTerm
200 Ne04522abda8448599801db2860c38c15 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Injections, Intravenous
202 rdf:type schema:DefinedTerm
203 Ne29bbe2676ba419284a31f2d6d58e5d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Aged
205 rdf:type schema:DefinedTerm
206 Nfc990374b7534adb9c069fa805a90433 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Drug Evaluation
208 rdf:type schema:DefinedTerm
209 Nfcff759ad56940f585737271958083b8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
210 schema:name Humans
211 rdf:type schema:DefinedTerm
212 Nff81882a37a94b0bb871e8fda1bad209 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Antigens, Neoplasm
214 rdf:type schema:DefinedTerm
215 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
216 schema:name Medical and Health Sciences
217 rdf:type schema:DefinedTerm
218 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
219 schema:name Clinical Sciences
220 rdf:type schema:DefinedTerm
221 sg:journal.1358129 schema:issn 0939-5555
222 1432-0584
223 schema:name Annals of Hematology
224 schema:publisher Springer Nature
225 rdf:type schema:Periodical
226 sg:person.01002544733.03 schema:affiliation grid-institutes:None
227 schema:familyName Tsamaloukas
228 schema:givenName Antonis
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002544733.03
230 rdf:type schema:Person
231 sg:person.01040552530.23 schema:affiliation grid-institutes:grid.412282.f
232 schema:familyName Sockel
233 schema:givenName Katja
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040552530.23
235 rdf:type schema:Person
236 sg:person.01127414674.14 schema:affiliation grid-institutes:grid.411327.2
237 schema:familyName Haas
238 schema:givenName Rainer
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127414674.14
240 rdf:type schema:Person
241 sg:person.01362464041.20 schema:affiliation grid-institutes:grid.411327.2
242 schema:familyName Germing
243 schema:givenName Ulrich
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20
245 rdf:type schema:Person
246 sg:person.0643404664.08 schema:affiliation grid-institutes:grid.411327.2
247 schema:familyName Neukirchen
248 schema:givenName Judith
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643404664.08
250 rdf:type schema:Person
251 sg:person.0670313557.25 schema:affiliation grid-institutes:grid.412282.f
252 schema:familyName Platzbecker
253 schema:givenName Uwe
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670313557.25
255 rdf:type schema:Person
256 sg:pub.10.1038/leu.2011.44 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023546509
257 https://doi.org/10.1038/leu.2011.44
258 rdf:type schema:CreativeWork
259 sg:pub.10.1038/sj.leu.2403239 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015449707
260 https://doi.org/10.1038/sj.leu.2403239
261 rdf:type schema:CreativeWork
262 sg:pub.10.1038/sj.leu.2404747 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011177675
263 https://doi.org/10.1038/sj.leu.2404747
264 rdf:type schema:CreativeWork
265 sg:pub.10.1038/sj.onc.1210380 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035428201
266 https://doi.org/10.1038/sj.onc.1210380
267 rdf:type schema:CreativeWork
268 grid-institutes:None schema:alternateName Private Practice, Hilden, Germany
269 schema:name Private Practice, Hilden, Germany
270 rdf:type schema:Organization
271 grid-institutes:grid.411327.2 schema:alternateName Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, Düsseldorf, Germany
272 schema:name Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, Düsseldorf, Germany
273 rdf:type schema:Organization
274 grid-institutes:grid.412282.f schema:alternateName Department of Medicine 1, University Hospital Carl Gustav Carus, Dresden, Germany
275 schema:name Department of Medicine 1, University Hospital Carl Gustav Carus, Dresden, Germany
276 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...